It’s only fair to share… BOFUTRELVIR Cas 2103278-86-8 Molecular Weight 452.55 Formula C25H32N4O4 UNII-T5UX5SKK2S; Mpro inhibitor 11A; 2103278-86-8; T5UX5SKK2S, DC-402234, DC402234, MPI-10 IUPAC/Chemical Name: N-[(2S)-3-cyclohexyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]propan-2-yl]-1H-indole-2-carboxamide N-[(2S)-3-cyclohexyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]propan-2-yl]-1H-indole-2-carboxamide Bofutrelvir has an additive antiviral effect when combined with Remdesivir FB2001 Bofutrelvir (FB2001) is a SARS-CoV-2 main protease Mpro inhibitor with an IC50 value of 53 nM and an EC50 value of 0.53 μM. Bofutrelvir exhibits potent antiviral efficacy …
Inavolisib
It’s only fair to share… Inavolisib WeightAverage: 407.378Monoisotopic: 407.140510438 Chemical FormulaC18H19F2N5O4 FDA APPROVED, 10/10/2024, Itovebi, To treat locally advanced or metastatic breast cancerDrug Trials Snapshot (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide Inavolisib, sold under the brand name Itovebi, is an anti-cancer medication used for the treatment of breast cancer.[2][3] It is an inhibitor and degrader of mutant phosphatidylinositol 3-kinase (PI3K) alpha.[4] The PI3K-mediated signalling pathway has shown to …
Bocodepsin
It’s only fair to share… Bocodepsin, OKI-179 CAS 1834513-65-3 1834513-67-5 (besylate) K5D067O1SW S-((3E)-4-((6S,9S)-12,12-DIMETHYL-4,8,11,14-TETRAOXO-9-(PROPAN-2-YL)-7-OXA -3,10,13-TRIAZA-1(2,4)-(1,3)THIAZOLACYCLOTETRADECAPHAN-6-YL)BUT-3-EN-1-YL) (2S)-2-AMINO-3-METHYLBUTANETHIOATES-(4-((7S,10S)-4,4-DIMETHYL-2,5,8,12-TETRAOXO-7-(PROPAN-2-YL)-9-OXA-16-THIA- 3,6,13,18-TETRAAZABICYCLO(13.2.1)OCTADECA-15(18),17-DIEN-10-YL)BUT-3-EN-1-YL) (2S)-2-AMINO-3-METHYLBUTANETHIOATE Molecular Weight 581.75 Formula C26H39N5O6S2 Phase I/II Malignant melanoma; Solid tumours 29 Jan 2025 OnKure Therapeutics completes the phase-I/II Nautilus trial in Malignant melanoma (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT05340621), …
Vanzacaftor
It’s only fair to share… Vanzacaftor FDA APPROVED vanzacaftor, tezacaftor, and deutivacaftor, 12/20/2024, Alyftrek , To treat cystic fibrosis (14S)-8-[3-(2-dispiro[2.0.24.13]heptan-7-ylethoxy)pyrazol-1-yl]-12,12-dimethyl-2,2-dioxo-2λ6-thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5(10),6,8,19(23),20-hexaen-4-one 13H-17,20-Methano-8,12-nitrilo-12H-pyrido[3,2-d][1,2,6,13]thiatriazacyclooctadecin-5(6H)-one, 2-[3-(2-dispiro[2.0.2.1]hept-7-ylethoxy)-1H-pyrazol-1-yl]-14,15,16,17,18,19-hexahydro-19,19-dimethyl-, 7,7-dioxide, (17S)- (14S)-8-[3-(2-Dispiro[2.0.24.13]heptan-7-ylethoxy)pyrazol-1-yl]-12,12-dimethyl-2,2-dioxo-2?6-thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5(10),6,8,19(23),20-hexaen-4-one (14S)-8-[3-(2-dispiro[2.0.24.13]heptan-7-ylethoxy)pyrazol-1-yl]-12,12-dimethyl-2,2-dioxo-2|E6-thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5(10),6,8,19(23),20-hexaen-4-one Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined …
Tegeprotafib
It’s only fair to share… Tegeprotafib CAS 2407610-46-0 Molecular Weight 326.30 Formula C13H11FN2O5S PTPN2/1-IN-1, YGY4WEM0NZ 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one Tegeprotafib (PTPN2/1-IN-1) (Compound 124) is an orally active PTPN1 and PTPN2 inhibitor with IC50s of 4.4 nM and 1-10 nM against PTPN2 and PTP1B, respectively. Cancer immunotherapy regimens targeting immune evasion mechanisms including checkpoint blockade (e.g., PD-1/PD-L1 and CTLA-4 blocking antibodies) have been …
Probenecid
It’s only fair to share… Probenecid 4-(dipropylsulfamoyl)benzoic acid C13H19NO4S, 285.359 FDA APPROVED, 10/25/2024, sulopenem etzadroxil, probenecid, Orlynvah, To treat uncomplicated urinary tract infections (uUTI)Drug Trial Snapshot Probenecid, also sold under the brand name Probalan, is a medication that increases uric acid excretion in the urine. It is primarily used in treating gout and hyperuricemia. Probenecid was developed as an alternative to caronamide[1] to …
Sulopenem
It’s only fair to share… Sulopenem (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid FDA APPROVED sulopenem etzadroxil, probenecid, 10/25/2024, To treat uncomplicated urinary tract infections (uUTI)Drug Trial Snapshot Sulopenem (CP-70,429) is a thiopenem antibiotic derivative from the penem family, which unlike most related drugs is orally active. It was developed in Japan in the 1990s, and has been approved to treat uncomplicated urinary tract infections …
Bleximenib
It’s only fair to share… Bleximenib CAS 2654081-35-1 WeightAverage: 599.796Monoisotopic: 599.395916661 Chemical FormulaC32H50FN7O3 2866179-95-3 (oxalate) (R)-N-ethyl-5-fluoro-N-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide oxalate Chemical Formula: C34H52FN7O7Exact Mass: 689.39Molecular Weight: 689.830Elemental Analysis: C, 59.20; H, 7.60; F, 2.75; N, 14.21; O, 16.23 \Bleximenib is under investigation in clinical trials NCT04811560 (A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia) and …
Revumenib
It’s only fair to share… Revumenib FDA APPROVED 11/15/2024, Revuforj, To treat relapsed or refractory acute leukemia N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-N-propan-2-ylbenzamide Ingredient UNII CAS InChI Key Revumenib citrate YL4RYN734D 2761046-45-9 UBXFWTFPYATLBT-SGBGZXBGSA-N Revumenib sesquifumarate 75HI05N8HS 2169919-22-4 AXNUWYROYVRYIM-OQIJCFCCSA-N Revumenib, sold under the brand name Revuforj, is an anti-cancer medication used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A) rearrangements.[1] It is designed to disrupt the …
Acoramidis
It’s only fair to share… Acoramidis 292.30 g/mol, C15H17FN2O3 3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-4-fluorobenzoic acid FDA APPROVED 11/22/2024, Attruby To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosisDrug Trials Snapshot Ingredient UNII CAS InChI Key Acoramidis hydrochloride VY9C88C2NV 2242751-53-5 MGFZEARHINUOMX-UHFFFAOYSA-N Acoramidis, sold under the brand name Attruby, is a medication used for the treatment of cardiomyopathy.[1] It is a near-complete (>90%) transthyretin stabilizer, developed to mimic the …